NeuroSearch A/S (NEUR) has received notification from Luxor Capital Group, LP
that the company has increased its ownership in NeuroSearch A/S.

Hereafter, Luxor Capital Group, LP holds more than 1,235,951 shares of DKK 20
nominal value corresponding to an ownership and voting rights of 5.03%.

Patrik Dahlen
CEO


Contact persons:
René Schneider, EVP & CFO, telephone: +45 4460 8700


About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in
CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a
pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique
orphan drug in Phase III for the treatment of Huntington's disease. NeuroSearch
is building commercial competences with a view to commercialising Huntexil®
through an in-house marketing and sales organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with
unique capabilities in the field of ion channels and CNS diseases. The company
has strategic drug discovery and development alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
NeuroSearch also has equity interests in a number of unlisted companies in the
Life Science industry.